Abstract
Background
Most guidelines and experts recommend against performance of thrombophilia testing in general, and specifically against testing patients on pharmacological anticoagulants, due to substantially increased risk of false positive identification. For example, vitamin K antagonist (VKA) therapy affects protein C (PC) and protein S (PS), as well as some clotting assays (e.g. as used to investigate activated PC resistance [APCR]). Although heparin may also affect clotting assays, most commercial methods contain neutralisers to make them ‘insensitive’ to therapeutic levels. Direct oral anticoagulants (DOACs) also affect a wide variety of thrombophilia assays, although most reported data has employed artificial in vitro spiked samples.
Methods
In the current report, data from our facility for the past 2.5 years has been assessed for all ‘congenital thrombophilia’ related tests, as evaluated against patient anticoagulant status. We processed 10,571 ‘thrombophilia’ related test requests, including antithrombin (AT; n=3470), PC (n=3569), PS (n=3585), APCR (n=2359), factor V Leiden (FVL; n=2659), and prothrombin gene mutation (PGM; n=2103).
Results
As expected, VKA therapy affected PC and PS, and despite manufacturer claims, also APCR. Most assays, as suggested by manufacturers, were largely resistant to heparin therapy. DOACs’ use was associated with falsely low APCR ratios (i.e. FVL-like effect) and somewhat unexpectedly, anti-Xa agents apixaban and rivaroxaban were also associated with lower AT and higher PS values.
Conclusions
It is concluded that ex-vivo data appears to confirm the potential for both false positive and false negative ‘thrombophilia’ events in patients on anticoagulant (including DOAC) treatment.
Acknowledgments
The author thanks the PathNet Application Specialists (PAS) Team, especially Violeta Ule Priebbenow, Igor Melnikov and Natasha Biktemirova for arranging the data extraction from our laboratory information system (LIS). Various staff from the author’s laboratory are thanked for the performance of the laboratory assays as reported here but as performed as part of their standard duties. New South Wales (NSW) Health Pathology is acknowledged for providing in-kind support to permit study completion. The views expressed in this paper are those of the author and are not necessarily those of NSW Health Pathology.
Author contributions: The author has accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Favaloro EJ, Pasalic L, Lippi G. Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing. Pathology 2017;49:639–43.10.1016/j.pathol.2017.04.011Search in Google Scholar PubMed
2. Favaloro EJ, Pasalic L, Curnow J, Lippi G. Laboratory monitoring or measurement of direct oral anticoagulants (DOACs): advantages, limitations and future challenges. Curr Drug Metab 2017;18:598–608.10.2174/1389200218666170417124035Search in Google Scholar PubMed
3. Lippi G, Franchini M, Favaloro EJ. Pharmacogenetics of vitamin K antagonists: useful or hype? Clin Chem Lab Med 2009;47:503–15.10.1515/CCLM.2009.140Search in Google Scholar PubMed
4. Bonar R, Favaloro EJ. Explaining and reducing the variation in inter-laboratory reported values for international normalised ratio. Thromb Res 2016;150:22–9.10.1016/j.thromres.2016.12.007Search in Google Scholar PubMed
5. Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: The ORBIT-AF II registry. J Am Coll Cardiol 2016;68:2597–604.10.1016/j.jacc.2016.09.966Search in Google Scholar PubMed
6. Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010;149:209–20.10.1111/j.1365-2141.2009.08022.xSearch in Google Scholar PubMed
7. Graham N, Rashiq H, Hunt BJ. Testing for thrombophilia: clinical update. Br J Gen Pract 2014;64:e120–2.10.3399/bjgp14X677310Search in Google Scholar PubMed PubMed Central
8. Howard LS, Hughes RJ. NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing. Thorax 2013;68:391–3.10.1136/thoraxjnl-2012-202376Search in Google Scholar PubMed
9. De Stefano V, Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the guidelines from scientific societies and working groups. Thromb Haemost 2013;110:697–705.10.1160/TH13-01-0011Search in Google Scholar PubMed
10. Carroll BJ, Piazza G. Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test? Vasc Med 2018;23:388–99.10.1177/1358863X18755927Search in Google Scholar PubMed
11. Ormesher L, Simcox LE, Tower C, Greer IA. ‘To test or not to test’, the arguments for and against thrombophilia testing in obstetrics. Obstet Med 2017;10:61–6.10.1177/1753495X17695696Search in Google Scholar PubMed PubMed Central
12. Gosselin RC, Adcock DM, Bates SM, Douxfils J, Favaloro EJ, Gouin-Thibault I, et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2018;118:437–50.10.1055/s-0038-1627480Search in Google Scholar PubMed
13. Bonar R, Favaloro EJ, Mohammed S, Pasalic L, Sioufi J, Marsden K. The effect of dabigatran on haemostasis tests: a comprehensive assessment using in-vitro and ex-vivo samples. Pathology 2015;47:355–64.10.1097/PAT.0000000000000252Search in Google Scholar PubMed
14. Bonar R, Favaloro EJ, Mohammed S, Ahuja M, Pasalic L, Sioufi J, et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 2016;48:60–71.10.1016/j.pathol.2015.11.025Search in Google Scholar PubMed
15. Favaloro EJ, Orsag I, Bukuya M, McDonald D. A nine-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations. Pathology 2002;34:348–55.10.1080/003130202760120526Search in Google Scholar PubMed
16. Mohammed S, Favaloro EJ. Laboratory testing for activated protein C resistance (APCR). Methods Mol Biol 2017;1646:137–43.10.1007/978-1-4939-7196-1_10Search in Google Scholar PubMed
17. Favaloro EJ. Diagnostic issues in Thrombophilia: a laboratory scientist’s view. Semin Thromb Hemost 2005;31:11–6.10.1055/s-2005-863800Search in Google Scholar PubMed
18. Favaloro EJ, McDonald D. Futility of testing for factor V Leiden. Blood Trans 2012;10:260–3.Search in Google Scholar
19. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009;7:1737–40.10.1111/j.1538-7836.2009.03555.xSearch in Google Scholar PubMed
20. Exner T, Michalopoulos N, Pearce J, Xavier R, Ahuja M. Simple method for removing DOACs from plasma samples. Thromb Res 2018;163:117–22.10.1016/j.thromres.2018.01.047Search in Google Scholar PubMed
21. Mou E, Kwang H, Hom J, Shieh L, Kumar A, Richman I, et al. Magnitude of potentially inappropriate thrombophilia testing in the inpatient hospital setting. J Hosp Med 2017;12:735–8.10.12788/jhm.2819Search in Google Scholar PubMed
22. Cox N, Johnson SA, Vazquez S, Fleming RP, Rondina MT, Kaplan D, et al. Patterns and appropriateness of thrombophilia testing in an academic medical center. J Hosp Med 2017;12:705–9.10.12788/jhm.2804Search in Google Scholar PubMed
23. Shen YM, Tsai J, Taiwo E, Gavva C, Yates SG, Patel V, et al. Analysis of thrombophilia test ordering practices at an academic center: a proposal for appropriate testing to reduce harm and cost. PLoS One 2016;11:e0155326.10.1371/journal.pone.0155326Search in Google Scholar PubMed PubMed Central
24. Kwon AJ, Roshal M, DeSancho MT. Clinical adherence to thrombophilia screening guidelines at a major tertiary care hospital. J Thromb Haemost 2016;14:982–6.10.1111/jth.13284Search in Google Scholar PubMed
25. Lippi G. Thrombophilia testing. Useful or hype? Clin Chem Lab Med 2014;52:467–9.10.1515/cclm-2013-0561Search in Google Scholar PubMed
26. Franchini M. The utility of thrombophilia testing. Clin Chem Lab Med 2014;52:495–7.10.1515/cclm-2013-0559Search in Google Scholar PubMed
27. Favaloro EJ. The futility of thrombophilia testing. Clin Chem Lab Med 2014;52:499–503.10.1515/cclm-2013-0560Search in Google Scholar PubMed
©2019 Walter de Gruyter GmbH, Berlin/Boston
